Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

  • Rocio I.R. MacIas - , Universidad de Salamanca, CIBER - Center for Biomedical Research Network (Author)
  • Vincenzo Cardinale - , University of Rome La Sapienza (Author)
  • Timothy J. Kendall - , University of Edinburgh (Author)
  • Matias A. Avila - , CIBER - Center for Biomedical Research Network, University of Navarra (Author)
  • Maria Guido - , University of Padua (Author)
  • Cedric Coulouarn - , Université de Rennes 1 (Author)
  • Chiara Braconi - , University of Glasgow (Author)
  • Adam E. Frampton - , University of Surrey (Author)
  • John Bridgewater - , University College London (Author)
  • Diletta Overi - , University of Rome La Sapienza (Author)
  • Stephen P. Pereira - , University College London (Author)
  • Marco Rengo - , University of Rome La Sapienza (Author)
  • Jakob N. Kather - , RWTH Aachen University (Author)
  • Angela Lamarca - , The Christie NHS Foundation Trust (Author)
  • Federica Pedica - , Vita-Salute San Raffaele University (Author)
  • Alejandro Forner - , CIBER - Center for Biomedical Research Network, University of Barcelona (Author)
  • Juan W. Valle - , The Christie NHS Foundation Trust (Author)
  • Eugenio Gaudio - , University of Rome La Sapienza (Author)
  • Domenico Alvaro - , University of Rome La Sapienza (Author)
  • Jesus M. Banales - , CIBER - Center for Biomedical Research Network, Hospital Universitario Donostia, University of Navarra (Author)
  • Guido Carpino - , Foro Italico University of Rome (Author)

Abstract

Cholangiocarcinoma (CCA) is a malignant tumour arising from the biliary system. In Europe, this tumour frequently presents as a sporadic cancer in patients without defined risk factors and is usually diagnosed at advanced stages with a consequent poor prognosis. Therefore, the identification of biomarkers represents an utmost need for patients with CCA. Numerous studies proposed a wide spectrum of biomarkers at tissue and molecular levels. With the present paper, a multidisciplinary group of experts within the European Network for the Study of Cholangiocarcinoma discusses the clinical role of tissue biomarkers and provides a selection based on their current relevance and potential applications in the framework of CCA. Recent advances are proposed by dividing biomarkers based on their potential role in diagnosis, prognosis and therapy response. Limitations of current biomarkers are also identified, together with specific promising areas (ie, artificial intelligence, patient-derived organoids, targeted therapy) where research should be focused to develop future biomarkers.

Details

Original languageEnglish
Pages (from-to)1669-1683
Number of pages15
JournalGut
Volume71
Issue number8
Publication statusPublished - 1 Aug 2022
Peer-reviewedYes
Externally publishedYes

External IDs

PubMed 35580963

Keywords

Sustainable Development Goals

ASJC Scopus subject areas

Keywords

  • CHOLANGIOCARCINOMA, HEPATOBILIARY CANCER, TUMOUR MARKERS

Library keywords